Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 9Terminated 3Unknown 1

Sponsor Class

OTHER 16INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Gynecologic 1

Conditions

Melanoma 2Ovarian Neoplasms 1

Interventions

pembrolizumab 183Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 53fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 39Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × poly ICLC × Clear all
NCT03162562 2020-12-22

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

CanariaBio Inc.

Phase 1 Terminated
10 enrolled
Gynecologic

Ovarian Neoplasms

NCT03597282 2020-09-03

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

BioNTech SE

Phase 1 Terminated
22 enrolled
Dermatologic

Melanoma

NCT02413827 2017-04-07

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Celldex Therapeutics

Phase 1/2 Terminated
9 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡